Advanced Accelerator Applications: Clinical Trials

22 trials sponsored by Advanced Accelerator Applications, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 terminated, 5 completed, 4 recruiting, 2 active not recruiting. 22 Phase 2, 7 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 222Terminated 7, Completed 5, Recruiting 4, Active not recruiting 2, Unknown 2, Suspended 1, Withdrawn 1
Phase 17Completed 3, Terminated 3, Withdrawn 1

Follow Advanced Accelerator Applications: new trials by email

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Phase 2RecruitingOHSU Knight Cancer Institute102026-06-302026-06-05
Radiopharmaceutical Treatment of Advanced Kidney Cancer
177Lu-PSMA-617 - Metastatic Clear Cell Renal Cell Carcinoma
Phase 2RecruitingEuropean Organisation for Research and Treatment of Cancer - EORTC482026-04-072026-06-04
Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer
[177Lu]Lu-PSMA-617, Ipilimumab - Very High Risk Prostate Carcinoma
Phase 1 / Phase 2TerminatedUniversity Hospital, Essen12025-08-252026-03-13
Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in
77 Lu-DOTA0-Tyr3-Octreotate - Metastatic Nasopharyngeal Cancer
Phase 2SuspendedNational Cancer Centre, Singapore252023-05-052026-05-22
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Lutetium [177Lu] oxodotreotide/dotatate - Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma
Phase 2Active not recruitingAdvanced Accelerator Applications112022-08-312026-02-12
EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC
177Lu-PSMA-617, Ipilimumab, Nivolumab - Prostatic Neoplasms, Genital Neoplasms, Male
Phase 2UnknownAustralian and New Zealand Urogenital and Prostate Cancer Trials Group932022-04-292023-12-15
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection, Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection, LUTATHERA® by intra-arterial hepatic (IAH) injection - Neuroendocrine Tumor, Liver Metastases
Phase 2RecruitingUniversity Hospital, Bordeaux232021-09-242025-07-23
177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
177Lu-DOTATATE - Neuroblastoma Recurrent, Neuroblastoma
Phase 2RecruitingJakob Stenman242021-05-192026-11-09
Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
Lutathera - Carcinoid Heart Disease, Carcinoid Syndrome
Phase 2UnknownKing's College Hospital NHS Trust202020-10-012020-08-04
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
177Lu-DOTA-tyr3-OCTREOTATE, Peptide Receptor Radiotherapy (PRRT) - Neuroendocrine Tumors, Pheochromocytoma
Phase 1 / Phase 2WithdrawnSue O'Dorisio2020-08-042021-06-08
Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer
177Lu-PSMA-617 - Prostate Cancer
Phase 2CompletedRadboud University Medical Center582020-07-202026-02-27
In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
177Lu-PSMA-617, Docetaxel - Metastatic Hormone Naive Prostate Cancer
Phase 2Active not recruitingPeter MacCallum Cancer Centre, Australia1302020-04-212025-07-11
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake
[177Lu]-NeoB, [68Ga]-NeoB, LCZ696 - Neoplasms
Phase 1 / Phase 2CompletedAdvanced Accelerator Applications352019-07-242026-07-28
[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
[68Ga]-NeoBOMB1 - Breast Cancer, Prostate Cancer
Phase 2TerminatedAdvanced Accelerator Applications192018-07-032020-10-23
68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
[68Ga]-PSMA-R2 - Prostate Cancer Metastatic
Phase 1 / Phase 2CompletedAdvanced Accelerator Applications302018-05-232020-11-17
Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
Nivolumab, 177Lu-DOTA0-Tyr3-Octreotate - Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage
Phase 1 / Phase 2CompletedGeorgetown University92017-11-202021-03-16
99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis
rhAnnexin V-128 - Spondyloarthritis
Phase 2TerminatedAdvanced Accelerator Applications52017-09-182019-12-13
99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer
99mTc-rhAnnexin V-128 - Breast Cancer, Doxorubicin Induced Cardiomyopathy
Phase 2TerminatedAdvanced Accelerator Applications142016-11-022020-12-11
99mTc-rhAnnexin V-128 Imaging for Carotid Atherosclerosis
99mTc-rhAnnexin V-128 - Carotid Artery Plaque
Phase 2TerminatedAdvanced Accelerator Applications392016-06-232020-10-09
Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis
99mTc-Annexin V-128 SPECT - Endocarditis, Thrombosis
Phase 1 / Phase 2TerminatedInstitut National de la Santé Et de la Recherche Médicale, France112016-02-052021-08-26

Showing 20 of 22. Sign in to see all of them.

Conditions studied

Neoplasms (4)  ·  Prostatic Neoplasms (4)  ·  Breast Neoplasms (3)  ·  Genital Neoplasms, Male (2)  ·  Neoplasms by Site (2)  ·  Neuroendocrine Tumors (2)  ·  Paraganglioma (2)  ·  Pheochromocytoma (2)  ·  Prostatic Diseases (2)  ·  Small Cell Lung Carcinoma (2)  ·  Spondylitis, Ankylosing (2)  ·  Urogenital Neoplasms (2)  ·  Arthritis, Psoriatic (1)  ·  Arthritis, Rheumatoid (1)  ·  Carcinoid Heart Disease (1)

Interventions

lutetium Lu 177 dotatate (7)  ·  Pluvicto (4)  ·  Ipilimumab (2)  ·  Nivolumab (2)  ·  Biopsy (1)  ·  Docetaxel (1)  ·  Ga(III)-DOTATOC (1)  ·  Injections (1)  ·  Lutetium (1)  ·  Lutetium-177 (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Specimen Handling (1)  ·  Sunitinib (1)  ·  Valsartan (1)  ·  copper dotatate CU-64 (1)

Countries

France (7)  ·  United States (7)  ·  Netherlands (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Austria (2)  ·  Canada (2)  ·  Cyprus (1)  ·  Denmark (1)  ·  Germany (1)  ·  Lithuania (1)  ·  Norway (1)  ·  Poland (1)  ·  Singapore (1)

Top investigators

Arun Azad, MBBS PhD FRACP (1)  ·  Chul Kim, MD (1)  ·  Daniel Tan, BSc, MBBS, PhD (1)  ·  Dominique Le Guludec, MD, PhD (1)  ·  Emmanuel Seront, MD (1)  ·  Jakob Stenman, MD PhD (1)  ·  James Nagarajah, Prof. (1)  ·  John Prior, MD, PhD (1)  ·  M. Sue O'Dorisio, MD, PhD (1)  ·  Michael Hofman, MBBS(Hons),FRACP,FAANMS,FICIS (1)  ·  Rodney F Pommier (1)  ·  Shahneen Sandhu, MBBS, FRACP (1)

Results publications

PMID 32616557, PMID 32928177, PMID 33189510, PMID 34736509, PMID 35359899, PMID 38753757, PMID 39293461, PMID 39915126, PMID 40198358, PMID 41073165, PMID 41926960, PMID 42225102

NIH funding

2023 (2), 2017 (1)